Navigation Links
Shionogi Inc. Announces Commercial Availability of KAPVAY™ (clonidine hydrochloride) Extended-Release Tablets for the Treatment of ADHD
Date:1/10/2011

hould not be used in patients with known hypersensitivity to clonidine.

KAPVAY™ can cause dose-related decreases in blood pressure and heart rate, use caution in treating patients who have a history of syncope or may have a condition that predisposes them to syncope, such as hypotension, orthostatic hypotension, bradycardia, or dehydration.  Use with caution in patients treated concomitantly with antihypertensives or other drugs that can reduce blood pressure or heart rate or increase the risk of syncope.

Somnolence/sedation were commonly reported adverse reactions in clinical studies with KAPVAY™.  Potential for additive sedative effects with central nervous system (CNS) depressant drugs, advise patients to avoid use with alcohol. Caution patients against operating heavy equipment or driving until they know how they respond to KAPVAY™.

Patients should be instructed not to discontinue KAPVAY™ therapy without consulting their physician due to the potential risk of withdrawal effects.  KAPVAY™ should be discontinued slowly in decrements of no more than 0.1 mg every 3 to 7 days.

In patients who have developed localized contact sensitization or other allergic reaction to clonidine in a transdermal system, substitution of oral clonidine hydrochloride therapy may be associated with the development of a generalized skin rash, urticaria, or angioedema.

Use cautiously in patients with vascular disease, cardiac conduction disease, or chronic renal failure:  Monitor carefully and uptitrate slowly.

Clonidine may potentiate the CNS-depressive effects of alcohol, barbiturates or other sedating drugs.

Use caution when KAPVAY™ is administered concomitantly with antihypertensive drugs, due to the additive pharmacodynamics effects (e.g. hypotension, syncope).

KAPVAY™ should not be used during pregnancy unless clearly needed.  Since clonidine hydrochloride is
'/>"/>

SOURCE Shionogi Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
2. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
3. BioCrysts Partner Shionogi Launches Peramivir In Japan Under The Name RAPIACTA
4. Shionogi Enters Into Exclusive License Agreement With QuatRx Pharmaceuticals To Market Ospemifene
5. Shionogi Inc. Announces FDA Approval of CUVPOSA™ for the Treatment of Chronic Severe Drooling in Pediatric Patients With Neurologic Conditions
6. Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014  Luoxis Diagnostics, ... MKT: AMPE), today announced that its academic collaborators ... and research potential for its novel RedoxSYS Diagnostic ... (ORP) in the body in response to injury ... of ORP as a clinical marker will be ...
(Date:10/20/2014)... , Oct. 20, 2014 Valeritas, Inc., ... designed for patients with Type 2 diabetes, announced today ... Chain Excellence Award. The award was presented October 16 ... Columbus, Ohio . ... judged across a variety of metrics specifically targeted at ...
(Date:10/20/2014)... Oct. 20, 2014  AnaptysBio, Inc., a leader ... today announced the appointment of Marco Londei ... will lead the preclinical and clinical development of ... are pleased to welcome Dr. Londei to AnaptysBio,s ... President and Chief Executive Officer of AnaptysBio. "Dr. ...
Breaking Medicine Technology:Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... , , ROCKVILLE, Md. , ... ) announced today that the company has decided to discontinue ... ROVI Pharmaceuticals ( Madrid : ROVI) to develop Novavax,s virus-like-particle ... .  This decision is due to the companies, inability to ...
... , SALT LAKE CITY , Feb. ... Corporation ("WorldHeart" or "Company"), a developer of mechanical circulatory systems, ... Company  received a NASDAQ Staff Deficiency Letter indicating that the ... Rule requires the Company to have at least three independent ...
Cached Medicine Technology:Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 2Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 3Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 4NASDAQ Stock Market Confirms WorldHeart's Compliance With NASDAQ Listing Rule 5605 2
(Date:10/22/2014)... 2014 On Saturday, October 25, 2014, the ... family health and fitness fair ¡Vive tu vida! Get Up! ... good nutrition for better health and wellness for people of ... and open to the public, will be held at Dean ... am to 1:00 pm. , “¡Vive tu Vida! Get ...
(Date:10/22/2014)... 22, 2014 Medical Solutions ... is happy to announce that our co-founder and ... Industry Analysts’ Staffing 100 for 2014. Anderson was ... most influential people in the staffing industry,” in ... the 13th-largest healthcare staffing company in the U.S., ...
(Date:10/22/2014)... 2014 For Dr. Iris Hunter, a job ... an extension of her life’s mission. Her extensive experience in ... owner of FirstLight HomeCare, make it clear that Hunter’s mission ... that my work makes a difference in the lives of ... so after much research, I felt ready to start on ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- The ... passengers arriving from Ebola-affected nations of West Africa ... screen them for infection with the virus. ... Jeh Johnson noted that 94 percent of air ... land at one of these five airports -- ...
(Date:10/22/2014)... Va. (PRWEB) October 22, 2014 ... Innovation , which is dedicated to distribute health ... of healthcare delivery worldwide announced the development of ... which patients expect when receiving healthcare. These are ... for patient-centered care: “providing care that is respectful ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2
... ... "CSPA has not had an opportunity for a detailed review ... cannot,make any definitive comment on this specific study, we can ... correlation of,various data. This process does not necessarily demonstrate a ...
... Pa., Oct. 12 Helping its,employees to live a ... Recently, the American Heart Association (AHA) recognized,SAE for those ... Friendly Company, an honor,presented to only a handful of ... What does it mean? In short, it means that ...
... Parametric Release(TM) Instrument Processor, TUCSON, Ariz., Oct. ... of The Manzi Mach 1 Cleaner-Processor, the only,Parametric ... a,fully integrated cleaning, sterilizing and rinsing system that ... This system is designed for,use by hospitals, medical ...
... October 12, 2007 -- Excerpta Medica, an Elsevier ... six decades, has merged with corporate sibling Elsevier ... agency with more than a decades experience creating ... brands. Excerpta Medica will now be able ...
... GNC -- along with thousands of,herb-loving individuals, ... National Herb Day 2007 tomorrow, Oct. 13. The ... of October by giving,customers free 28-ct Mega Men(R) ... or more on herbs. National Herb Day ...
... only real-time PCR test for HIV, INDIANAPOLIS, Oct. ... its 1,700 hospital members access in,August to the Roche ... test for HIV offered to its members. Premier ... and COBAS(R) TaqMan(R) Analyzer to its existing three-year,molecular contract ...
Cached Medicine News:Health News:Consumer Specialty Products Association Responds to European Study Investigating Spray Products and Asthma 2Health News:FDA Grants Clearance to Langford IC Systems, Inc. 2Health News:FDA Grants Clearance to Langford IC Systems, Inc. 3Health News:GNC Honors Herb Day Tomorrow (and All Month Long) 2Health News:Nation's Largest Healthcare Alliance Adds Roche HIV-1 Test to Existing Contract 2Health News:Nation's Largest Healthcare Alliance Adds Roche HIV-1 Test to Existing Contract 3
9.5" overall length, 4.5" handle....
15" overall length, 9" handle....
...
EDM Ventricular Drainage Kit, with Drip Chamber with and without Bioglide are fabricated of radiopaque (barium impregnated) silicone tubing, and are packaged with stainless steel stylets inserted in ...
Medicine Products: